Ipsen Archives -

News/ News/ News/ Oncology/ R&D

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

Phil Taylor chemotherapy, Ipsen, Oncology, Onivyde, Servier, small cell lung cancer 0 Comment

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

https://pharmaphorum.com/news/phase-3-lung-cancer-fail-dents-prospects-of-ipsen-serviers-onivyde/

News/ News/ News/ Oncology/ R&D

Ipsen makes TCR play, grabbing two I-O therapies from Marengo

Phil Taylor Ipsen, Marengo Therapeutics, Oncology, partnering, TCR 0 Comment

Ipsen has joined the ranks of companies working on T cell receptor (TCR) therapies for cancer, paying $45

Ipsen makes TCR play, grabbing two I-O therapies from Marengo

https://pharmaphorum.com/news/ipsen-makes-tcr-play-grabbing-two-i-o-therapies-from-marengo/

News/ News/ News/ Oncology/ Sales and Marketing

Ipsen beefs up in oncology, buying US biopharma Epizyme

Phil Taylor Epizyme, Ipsen, M&A, Oncology, Tazverik 0 Comment

The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its

Ipsen beefs up in oncology, buying US biopharma Epizyme

https://pharmaphorum.com/news/ipsen-beefs-up-in-oncology-buying-us-biopharma-epizyme/

News/ News/ Sales and Marketing

Ipsen plans sale of consumer health business for €350m

Phil Taylor consumer health, Ipsen, M&A, Mayoly Spindler 0 Comment

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma

Ipsen plans sale of consumer health business for €350m

https://pharmaphorum.com/news/ipsen-plans-sale-of-consumer-health-business-for-e350m/

Market Access/ News/ News

After FDA setback, Ipsen gets first OK for rare disease drug palovarotene

Phil Taylor Canada, garetosmab, Ipsen, Orphan drug, rare disease, Regeneron, Sohonos 0 Comment

After regulatory hold-ups in the US and Europe, Ipsen has claimed a confidence-boosting approval in Canada for palovarotene,

After FDA setback, Ipsen gets first OK for rare disease drug palovarotene

https://pharmaphorum.com/news/after-fda-setback-ipsen-gets-first-ok-for-rare-disease-drug-palovarotene/

Oncology/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Putting patient perspectives at the heart of kidney cancer research

mike.hammerton@pharmaphorum.com cancer, Ipsen, kidney cancer, patients, R&D, renal cell carcinoma, RWE 0 Comment

Commissioned by Ipsen. Ipsen’s Steven Hildemann looks at how we can harness the power of patient perspectives in

Putting patient perspectives at the heart of kidney cancer research

https://pharmaphorum.com/patients/patient-perspectives-kidney-cancer-research/

News/ News/ R&D

Ipsen places €480m bet on Genfit’s liver drug elafibranor

Phil Taylor elafibranor, Genfit, hepatology, Ipsen, partnering, primary biliary cholangitis 0 Comment

Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis

Ipsen places €480m bet on Genfit’s liver drug elafibranor

https://pharmaphorum.com/news/ipsen-places-e480m-bet-on-genfits-liver-drug-elafibranor/

Market Access/ News/ News

Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE review

Phil Taylor Bristol-Myers Squibb, Cabometyx, HEOR, immuno-oncology, Ipsen, kidney cancer, market access, Oncology, Opdivo, SMC 0 Comment

Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo

Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE review

https://pharmaphorum.com/news/scotland-backs-cabometyx-combo-for-kidney-cancer-amid-stalled-nice-review/

Market Access/ News/ News

Ipsen hit by new palaver for rare disease drug palovarotene

Phil Taylor fda, Ipsen, Orphan drug, rare disease 0 Comment

Just as Ipsen’s $1 billion bet on rare bone disease drug palovarotene seemed to be nearing the finish

Ipsen hit by new palaver for rare disease drug palovarotene

https://pharmaphorum.com/news/ipsen-hit-by-new-palaver-for-rare-disease-drug-palovarotene/

Trending

Ipsen

Login